Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
275 participants
INTERVENTIONAL
2013-11-30
2015-08-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase III Study of ASP2151 in Herpes Simplex Patients
NCT01959295
Phase III Study of ASP2151 in Herpes Zoster Patients
NCT01959841
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
NCT00486200
Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food
NCT02852876
Dose-finding Study of ASP2151 in Subjects With Herpes Zoster
NCT00487682
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ASP2151
ASP2151
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ASP2151
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Recurrent labial/facial herpes: Patients with at least 10 papulae or vesicles/pustules
* Recurrent genital herpes: Patients with at least 5 papules or vesicles/pustules on the genital organs or in the genital and circumanal region
* Kaposi varicelliform eruption: Patients with major skin symptoms of papulae or vesicles
2. Patients who can start receiving the study drug within 48 hours after onset of rash
3. Age: 16 years or older, but younger than 80 years
Exclusion Criteria
2. Patients with two or more types of herpes simplex.
3. An extreme decline in immune function
4. Presence of serious complications
5. Patients found to meet any of the following conditions based on laboratory tests performed within 14 days before informed consent:
* AST or ALT ≥ 2.5 x upper limit of normal
* Platelet count \< lower limit of normal
* Serum creatinine ≥ 1.5 mg/dL
* Creatinine clearance \< 30 mL/min
6. Current or previous history of malignant tumor within 5 years before informed consent
7. Diagnosis of autoimmune disease
16 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maruho Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sapporo Hokkaido Japan
Sapporo, , Japan
Oota-ku Tokyo Japan
Tokyo, , Japan
Yokohama Kanagawa Japan
Yokohama, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M522101-J12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.